Participants 842 975 7
safety profile of anacetrapib in patients with coronary heart disease (CHD) or CHD risk equivalents (clinical trials.gov NCT00685776)
Participants 977 1196 4
Eligible patients at National Cholesterol Education Program-Adult Treatment Panel III LDL-C treatment goal on a statin, with or without other lipid-modifying medications, are treated with anacetrapib, 100 mg, or placebo
Participants 1725 1846 6
A total of 2,757 patients were screened at 153 centers in 20 countries, and 1,623 patients were randomized into the trial
